title: Purinergic modulation of cardiovascular function in the rat locus coeruleus.
abstract: 1 The purpose of the present study was to determine whether purines exerted a physiological role in central cardiovascular modulation at the level of the locus coeruleus (LC). 2 In pentobarbitone-anaesthetised Wistar-Kyoto rats, unilateral microinjection of ATP or alpha,beta-methyleneATP into the LC elicited dose-related decreases in blood pressure and heart rate. Unilateral microinjection of the P2 purinoceptor antagonists suramin and PPADS, caused pressor and tachycardic responses. Administration of the selective P2X(1) receptor antagonist NF-279 had no effect. While both ATP and L-glutamate (L-GLU) resulted in depressor responses after intra-LC microinjection, following intra-LC microinjection of P2 purinoceptor antagonists into the LC, the effects of subsequent administration of either ATP or L-GLU were functionally reversed, such that a pressor response ensued. 3 Microinjection of noradrenaline into the LC caused an increase in blood pressure and heart rate; however, the alpha(2)-adrenoceptor antagonist idazoxan had no cardiovascular effects, but did prevent the pressor response to PPADS or suramin. In addition, coinjection of idazoxan with either suramin or PPADS abolished the ATP and L-GLU mediated pressor responses observed following either suramin or PPADS administration. 4 The present data suggest that firstly, purines are capable of acting within the LC to ultimately modulate the cardiovascular system and secondly, that there is apparently a functional interaction between tonically active purinergic and noradrenergic systems within the LC of the rat.
authors.affiliation: Department of Pharmacology, P.O. Box 13E, Monash University, Victoria 3800, Australia. Song.Yao@bristol.ac.uk
authors.forename: Song T
authors.initials: ST
authors.lastname: Yao
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lawrence
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D008125:Locus Coeruleus / Q000187:drug effects / Q000502:physiology*; D008297:Male; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011921:Rats, Inbred WKY; D018048:Receptors, Purinergic P2 / Q000502:physiology*
chemical_list: D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D000255:Adenosine Triphosphate
references.citation: J Neurosci. 1981 Aug;1(8):876-86
references.pmid: 7346592
references.citation: Neuroreport. 1994 Aug 15;5(13):1601-4
references.pmid: 7819528
references.citation: Physiol Rev. 1983 Jul;63(3):844-914
references.pmid: 6308694
references.citation: Exp Brain Res. 1984;55(1):145-51
references.pmid: 6745345
references.citation: Am J Physiol. 1984 Oct;247(4 Pt 2):H675-81
references.pmid: 6496709
references.citation: Can J Physiol Pharmacol. 1985 Jun;63(6):599-605
references.pmid: 4041999
references.citation: Brain Res. 1985 Dec 9;358(1-2):77-84
references.pmid: 4075133
references.citation: Neurosci Lett. 1985 Oct 24;61(1-2):25-9
references.pmid: 4080257
references.citation: Science. 1986 Nov 7;234(4777):734-7
references.pmid: 3775363
references.citation: Neurosci Lett. 1986 Nov 21;71(3):299-305
references.pmid: 3025783
references.citation: Hypertension. 1987 Jun;9(6 Pt 2):III110-3
references.pmid: 3596777
references.citation: Brain Res. 1987 Jun 23;414(1):119-32
references.pmid: 2887237
references.citation: Brain Res Bull. 1988 Aug;21(2):191-9
references.pmid: 2461245
references.citation: J Comp Neurol. 1999 Sep 27;412(3):410-28
references.pmid: 10441230
references.citation: J Comp Neurol. 2000 Nov 27;427(4):485-507
references.pmid: 11056460
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):340-50
references.pmid: 11111828
references.citation: Neuroscience. 2001;102(3):593-602
references.pmid: 11226696
references.citation: J Physiol. 2003 Oct 1;552(Pt 1):197-211
references.pmid: 12878756
references.citation: J Pharmacol Sci. 2004 Feb;94(2):153-60
references.pmid: 14978353
references.citation: Br J Pharmacol. 2004 Sep;143(1):119-31
references.pmid: 15345659
references.citation: Kurume Med J. 2004;51(2):109-23
references.pmid: 15373228
references.citation: Brain Res. 1976 Aug 13;112(2):413-9
references.pmid: 8191
references.citation: Brain Res. 1979 Aug 17;172(1):174-8
references.pmid: 466462
references.citation: Brain Res. 1980 Feb 10;183(2):301-11
references.pmid: 7353141
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):26-30
references.pmid: 6116197
references.citation: Science. 1982 Mar 12;215(4538):1394-6
references.pmid: 6278591
references.citation: J Neurosci. 1988 Oct;8(10):3644-57
references.pmid: 3193175
references.citation: Nature. 1989 Aug 24;340(6235):639-42
references.pmid: 2570354
references.citation: J Neurosci. 1991 Mar;11(3):760-9
references.pmid: 1672153
references.citation: Trends Pharmacol Sci. 1991 Sep;12(9):319-24
references.pmid: 1658999
references.citation: Neuroscience. 1992 Jun;48(4):941-52
references.pmid: 1630630
references.citation: Eur J Pharmacol. 1992 Mar 17;213(1):71-7
references.pmid: 1499658
references.citation: Eur J Pharmacol. 1992 Jul 7;217(2-3):217-9
references.pmid: 1330591
references.citation: Brain Res. 1993 Jan 8;600(1):56-62
references.pmid: 8093676
references.citation: J Neurosci. 1993 Mar;13(3):894-9
references.pmid: 8441014
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1993 Jan;347(1):21-7
references.pmid: 8446180
references.citation: Neurosci Lett. 1993 Apr 16;153(1):1-4
references.pmid: 8099722
references.citation: Br J Pharmacol. 1994 Mar;111(3):913-7
references.pmid: 8019769
references.citation: Neuroscience. 1994 Jul;61(2):199-202
references.pmid: 7969901
references.citation: Br J Pharmacol. 1994 Nov;113(3):815-22
references.pmid: 7858872
references.citation: Brain Res Bull. 1994;35(5-6):513-9
references.pmid: 7859109
references.citation: Br J Pharmacol. 1995 May;115(2):302-6
references.pmid: 7670731
references.citation: Nature. 1995 Oct 5;377(6548):432-5
references.pmid: 7566120
references.citation: Mol Pharmacol. 1995 Oct;48(4):569-73
references.pmid: 7476880
references.citation: J Physiol. 1995 Jul 1;486 ( Pt 1):33-46
references.pmid: 7562642
references.citation: EMBO J. 1996 Jan 2;15(1):55-62
references.pmid: 8598206
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3684-8
references.pmid: 8622997
references.citation: J Neurosci. 1996 Apr 15;16(8):2495-507
references.pmid: 8786426
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;352(6):585-96
references.pmid: 9053729
references.citation: J Pharmacol Exp Ther. 1996 Nov;279(2):967-74
references.pmid: 8930206
references.citation: Eur J Pharmacol. 1996 Nov 21;315(3):255-61
references.pmid: 8982662
references.citation: Br J Pharmacol. 1997 Oct;122(3):423-30
references.pmid: 9351497
references.citation: Neuropharmacology. 1997 Sep;36(9):1127-39
references.pmid: 9364468
references.citation: Neuropharmacology. 1997 Sep;36(9):1229-42
references.pmid: 9364478
references.citation: J Neurosci. 1998 Mar 1;18(5):1704-12
references.pmid: 9464995
references.citation: Brain Res. 1998 Jul 20;799(2):278-84
references.pmid: 9675311
references.citation: Pharmacol Rev. 1998 Sep;50(3):413-92
references.pmid: 9755289
references.citation: J Neurosci. 1999 Jan 15;19(2):737-46
references.pmid: 9880594
references.citation: J Comp Neurol. 1999 Apr 28;407(1):11-32
references.pmid: 10213185
references.citation: Neuroscience. 1999;91(2):621-9
references.pmid: 10366019
references.citation: Neurosci Lett. 1994 Jun 20;174(2):188-92
references.pmid: 7970176
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1982 Oct;321(1):38-43
references.pmid: 6292740